Abstract
Overweight and obesity are associated with an increased risk of developing many types of cancer, including breast cancer. Moreover, increased body mass index (BMI) seems to be associated with a worse prognosis in patients with HER2-positive early breast cancer. However, little is known about the impact of BMI on the clinical outcomes of HER2-positive metastatic breast cancer (MBC). This was a multicenter retrospective cohort study including 329 consecutive patients with HER2-positive MBC treated with first-line trastuzumab-based regimens. BMI at the time of MBC diagnosis was collected. World Health Organization BMI categories were used: underweight
Original language | Undefined/Unknown |
---|---|
Pages (from-to) | 142-147 |
Number of pages | 6 |
Journal | Breast |
Volume | 37 |
DOIs | |
Publication status | Published - Feb 1 2018 |
Keywords
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols, therapeutic use
- Body Mass Index
- Breast Neoplasms, drug therapy, metabolism, pathology
- Disease-Free Survival
- Female
- Humans
- Kaplan-Meier Estimate
- Middle Aged
- Neoplasm Metastasis
- Proportional Hazards Models
- Receptor, ErbB-2, metabolism
- Retrospective Studies
- Survival Rate
- Trastuzumab, administration & dosage
- Treatment Outcome
- Body mass index
- HER2-positive
- Metastatic breast cancer
- Trastuzumab